started · updated
AMED approves subsidy for cervical cancer regenerative medicine project
The Japan Agency for Medical Research and Development (AMED) has officially approved a subsidy for a project focused on developing manufacturing processes for Tumor-Infiltrating Lymphocyte (TIL) regenerative medicine products. This project specifically targets the treatment of advanced and recurrent cervical cancer.
The subsidy period is scheduled to run from September 14, 2026, to March 31, 2027. The expected grant amount for the 2026 fiscal year is approximately 79,993,000 yen. The final amount will be confirmed following official notification from AMED.
Entities
Sources
ピクサーの名シーンをスマホに、PGAから『シネマコレクション ステッカー』が登場
[news.cube-soft.jp]